Hypoxia-inducible factor: A potential therapeutic target for rheumatoid arthritis

Current Drug Targets

Volumn 14, Issue 6, 2013, Pages 700-707

  Zhao, Xuli ^a   Yue, Ye ^b   Cheng, Wengxiang ^b   Li, Jingchao ^b   Hu, Yiping ^b   Qin, Ling ^b   Zhang, Peng ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Angiogenesis; Hypoxia inducible factor; Regulation; Rheumatoid arthritis; Therapeutic target; Tumor therapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA CHEMOKINE; ANTHRACYCLINE; ASCORBIC ACID; BETA CHEMOKINE; BORTEZOMIB; CERTOLIZUMAB PEGOL; CX3C CHEMOKINE; FIBROBLAST GROWTH FACTOR; FLAVOPIRIDOL; HYPOXIA INDUCIBLE FACTOR; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR; POLYAMIDE; PREDNISONE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SCATTER FACTOR; STROMELYSIN; TRANSFORMING GROWTH FACTOR; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARTILAGE DEGENERATION; CELL METABOLISM; CELL MIGRATION; CELL SURVIVAL; DNA BINDING; ENERGY RESOURCE; GENE EXPRESSION; GENE MUTATION; GLYCOLYSIS; HUMAN; INFLAMMATORY CELL; MICROENVIRONMENT; OXYGEN TENSION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SYNOVIOCYTE;

ARTHRITIS, RHEUMATOID; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; HUMANS; MOLECULAR TARGETED THERAPY; TRANSCRIPTION FACTORS;

EID: 84878562009     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314060010     Document Type: Article

References (109)

1. Lund-Olesen K. Oxygen tension in synovial fluids. Arthritis Rheum 1970; 13(6): 769-76.
2. Sivakumar B, Akhavani MA, Winlove CP, Taylor PC, Paleolog EM, Kang N. Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. J Hand Surg Am 2008; 33(1): 49-58.
3. Lee YA, Kim JY, Hong SJ, et al. Synovial proliferation differentially affects hypoxia in the joint cavities of rheumatoid arthritis and osteoarthritis patients. Clin Rheumatol 2007; 26(12): 2023-9.
4. Bodamyali T, Stevens CR, Billingham ME, Ohta S, Blake DR. Influence of hypoxia in inflammatory synovitis. Ann Rheum Dis 1998; 57(12): 703-10.
5. Ahn JK, Koh EM, Cha HS, et al. Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford) 2008; 47(6): 834-9.
6. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12(12): 5447-54.
7. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005; 46(1): 31-6.
8. Semenza GL. Regulation of cancer cell metabolism by hypoxiainducible factor 1. Semin Cancer Biol 2009; 19(1): 12-6.
9. Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 2007; 26(14): 2027-38.
10. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004; 57(10): 1009-14.
11. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92(12):5510-4.
12. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 271(30): 17771-8.
13. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun 2001; 287(4): 808-13.
14. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002; 277(36): 32405-8.
15. Jain S, Maltepe E, Lu MM, Simon C, Bradfield CA. Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech Dev 1998; 73(1): 117-23.
16. Uchida T, Rossignol F, Matthay MA, et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem 2004; 279(15): 14871-8.
17. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol 2008; 586(Pt 17): 4055-9.
18. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9(6): 677-84.
19. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003; 112(5): 645-57.
20. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6(4): 273-86.
21. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006; 21(5): 557-66.
22. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16(9): 4604-13.
23. Takeda N, Maemura K, Imai Y, et al. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res 2004; 95(2): 146-53.
24. Jung F, Palmer LA, Zhou N, Johns RA. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res 2000; 86(3): 319-25.
25. Willam C, Koehne P, Jurgensen JS, et al. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ Res 2000; 87(5): 370-7.
26. Yamakawa M, Liu LX, Date T, et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 2003; 93(7): 664-73.
27. Abdulmalek K, Ashur F, Ezer N, Ye F, Magder S, Hussain SN. Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. Am J Physiol Lung Cell Mol Physiol 2001; 281(3): L582-90.
28. Schultz K, Fanburg BL, Beasley D. Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2006; 290(6): H2528-34.
29. Kuwabara K, Ogawa S, Matsumoto M, et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and plateletderived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci U S A 1995; 92(10): 4606-10.
30. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94(15): 8104-9.
31. Akhavani MA, Madden L, Buysschaert I, Sivakumar B, Kang N, Paleolog EM. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther 2009; 11(3): R64.
32. Pablos JL, Santiago B, Galindo M, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol 2003; 170(4): 2147-52.
33. Blades MC, Ingegnoli F, Wheller SK, et al. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum 2002; 46(3): 824-36.
34. Nanki T, Hayashida K, El-Gabalawy HS, et al. Stromal cellderived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000; 165(11): 6590-8.
35. Zhang WW, Lin M. HIF-1α, SDF-1α and VEGF gene expression affected by HIF-1α siRNA in MSCs. Heart 2010; 96(3): A32-A3.
36. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002; 46(10): 2587-97.
37. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10(8): 858-64.
38. Ishikawa T, Nakashiro K, Klosek SK, et al. Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol Rep 2009; 21(3): 707-12.
39. Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198(9): 1391-402.
40. Kohler T, Reizis B, Johnson RS, Weighardt H, Forster I. Influence of hypoxia-inducible factor 1alpha on dendritic cell differentiation and migration. Eur J Immunol 2012; 42(5): 1226-36.
41. Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2006; 20(5): 983-1002.
42. Yang S, Kim J, Ryu JH, et al. Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med 2010; 16(6): 687-93.
43. Ryu JH, Shin Y, Huh YH, Yang S, Chun CH, Chun JS. Hypoxiainducible factor-2alpha regulates Fas-mediated chondrocyte apoptosis during osteoarthritic cartilage destruction. Cell Death Differ 2012; 19(3): 440-50.
44. Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr 2007; 39(3): 223-9.
45. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 2009; 9(9): 1084-101.
46. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3(3): 177-85.
47. Zhang H, Bosch-Marce M, Shimoda LA, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008; 283(16): 10892-903.
48. Peyssonnaux C, Cejudo-Martin P, Doedens A, Zinkernagel AS, Johnson RS, Nizet V. Cutting edge: Essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharideinduced sepsis. J Immunol 2007; 178(12): 7516-9.
49. Brandt S, Takala J, Lepper PM. The Role of Hypoxia and Inflammation in the Expression and Regulation of Proteins Regulating Iron Metabolism. In: Vincent JK, editor. Yearbook of Intensive Care and Emergency Medicine 2008. p. 473-80.
50. Gale DP, Maxwell PH. The role of HIF in immunity. Int J Biochem Cell Biol 2010; 42(4): 486-94.
51. Sitkovsky M, Lukashev D. Regulation of immune cells by localtissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 2005; 5(9): 712-21.
52. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394(6692): 485-90.
53. Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Ann Rheum Dis 2005; 64(7): 971-80.
54. Giatromanolaki A, Sivridis E, Maltezos E, et al. Upregulated hypoxia inducible factor-1alpha and-2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003; 5(4): R193-201.
55. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxiainducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95(14): 7987-92.
56. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399(6733): 271-5.
57. Wei W, Yu XD. Hypoxia-inducible factors: crosstalk between their protein stability and protein degradation. Cancer Lett 2007; 257(2): 145-56.
58. Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998; 92(7): 2260-8.
59. Semenza GL, Agani F, Booth G, et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997; 51(2): 553-5.
60. Appelhoff RJ, Tian YM, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279(37): 38458-65.
61. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22(16): 4082-90.
62. Dann CE 3rd, Bruick RK, Deisenhofer J. Structure of factorinhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc Natl Acad Sci USA 2002; 99(24): 15351-6.
63. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15(20): 2675-86.
64. Freedman SJ, Sun ZY, Poy F, et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 2002; 99(8): 5367-72.
65. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE. Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci USA 2002; 99(8): 5271-6.
66. Westra J, Brouwer E, Bos R, Posthumus MD, et al. Regulation of cytokine-induced HIF-1alpha expression in rheumatoid synovial fibroblasts. Ann N Y Acad Sci 2007; 1108: 340-8.
67. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999; 94(5): 1561-7.
68. Scharte M, Han X, Bertges DJ, Fink MP, Delude RL. Cytokines induce HIF-1 DNA binding and the expression of HIF-1-dependent genes in cultured rat enterocytes. Am J Physiol Gastrointest Liver Physiol 2003; 284(3): G373-84.
69. Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J, Mochan E. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 2000; 350 Pt 1: 307-12.
70. Ramadori P, Ahmad G, Ramadori G. Cellular and molecular mechanisms regulating the hepatic erythropoietin expression during acute-phase response: a role for IL-6. Lab Invest 2010; 90(9): 1306-24.
71. Briggs JJ. Role of Stat3 in regulating hif-1alpha expression and tumor angiogenesis. Tempa: University of south florida 2005.
72. Kim J, Shao Y, Kim SY, et al. Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway. Mol Biol Cell 2008; 19(2): 433-44.
73. Gelderman KA, Hultqvist M, Olsson LM, et al. Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies. Antioxid Redox Signal 2007; 9(10): 1541-67.
74. Cuzzocrea S. Role of nitric oxide and reactive oxygen species in arthritis. Curr Pharm Des 2006; 12(27): 3551-70.
75. Bonello S, Zahringer C, BelAiba RS, et al. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 2007; 27(4): 755-61.
76. Sandau KB, Fandrey J, Brune B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 2001; 97(4): 1009-15.
77. Shi YH, Bingle L, Gong LH, Wang YX, Corke KP, Fang WG. Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology 2007; 39(4): 396-400.
78. Iqbal S, Zhang S, Driss A, et al. PDGF upregulates Mcl-1 through activation of beta-catenin and HIF-1alpha-dependent signaling in human prostate cancer cells. Plos One 2012; 7(1): e30764.
79. Lee SH, Koo KH, Park JW, et al. HIF-1 is induced via EGFR activation and mediates resistance to anoikis-like cell death under lipid rafts/caveolae-disrupting stress. Carcinogenesis 2009; 30(12): 1997-2004.
80. Tacchini L, Dansi P, Matteucci E, Desiderio MA. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 2001; 22(9): 1363-71.
81. Tacchini L, De Ponti C, Matteucci E, Follis R, Desiderio MA. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 2004; 25(11): 2089-100.
82. Sinha S, Koul N, Dixit D, Sharma V, Sen E. IGF-1 induced HIF-1alpha-TLR9 cross talk regulates inflammatory responses in glioma. Cell Signal 2011; 23(11): 1869-75.
83. McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 2006; 281(34): 24171-81.
84. Werth N, Beerlage C, Rosenberger C, et al. Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. Plos One 2010; 5(7): e11576.
85. Rodolico V, Arancio W, Amato MC, et al. Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein. Infect Agent Cancer 2011; 6(1): 18.
86. Nishi K, Oda T, Takabuchi S, et al. LPS induces hypoxia-inducible factor 1 activation in macrophage-differentiated cells in a reactive oxygen species-dependent manner. Antioxid Redox Signal 2008; 10(5): 983-95.
87. Kim CH, Cho YS, Chun YS, Park JW, Kim MS. Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res 2002; 90(2): E25-33.
88. Chang H, Shyu KG, Wang BW, Kuan P. Regulation of hypoxiainducible factor-1alpha by cyclical mechanical stretch in rat vascular smooth muscle cells. Clin Sci (Lond) 2003; 105(4): 447-56.
89. Kawabe S, Yokoyama Y. Role of hypoxia-inducible factor alpha in response to hypoxia and heat shock in the Pacific oyster Crassostrea gigas. Mar Biotechnol (NY) 2012; 14(1): 106-19.
90. Shein NA, Horowitz M, Alexandrovich AG, Tsenter J, Shohami E. Heat acclimation increases hypoxia-inducible factor 1alpha and erythropoietin receptor expression: implication for neuroprotection after closed head injury in mice. J Cereb Blood Flow Metab 2005; 25(11): 1456-65.
91. Li YM, Zhou BP, Deng J, Pan Y, Hay N, Hung MC. A hypoxiaindependent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 2005; 65(8): 3257-63.
92. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005; 37(3): 535-40.
93. Qu Z, Garcia CH, O'Rourke LM, Planck SR, Kohli M, Rosenbaum JT. Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. Arthritis Rheum 1994; 37(2): 212-20.
94. Pap T, Nawrath M, Heinrich J, et al. Cooperation of Ras-and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2004; 50(9): 2794-802.
95. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002; 99(15): 10025-30.
96. Muller-Ladner U, Gay S. MMPs and rheumatoid synovial fibroblasts: Siamese twins in joint destruction? Ann Rheum Dis 2002; 61(11): 957-9.
97. Cunnane G, FitzGerald O, Hummel KM, et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001; 44(8): 1744-53.
98. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423(6937): 356-61.
99. Haas CS, Amin MA, Allen BB, et al. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 2006; 54(8): 2402-14.
100. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33(4): 207-14.
101. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29(5): 625-34.
102. Wang R, Zhou S, Li S. Cancer therapeutic agents targeting hypoxia-inducible factor-1. Curr Med Chem 2011; 18(21): 3168-89.
103. ODell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. New Engl J Med 1996; 334(20): 1287-91.
104. Alarcon GS, Tracy IC, Blackburn WD. Methotrexate in Rheumatoid-Arthritis-Toxic Effects as the Major Factor in Limiting Long-Term Treatment. Arthritis and Rheumatism 1989; 32(6): 671-6.
105. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360(9339): 1071-3.
106. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295(19): 2275-85.
107. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52(11): 3403-12.
108. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349(20): 1907-15.
109. Defranoux N, Hurez VJ, Michelson SG, Shoda LK, Wennerberg LG. Treatment of rheumatoid arthritis with hypoxia inducible factor-1alpha antagonists. United states patent: US 20050148496-A1. Jul.7,2005.